Online inquiry

IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15347MR)

This product GTTS-WQ15347MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ENG gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000118.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2022
UniProt ID P17813
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15347MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5527MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ4393MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ10551MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ7517MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ13955MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4024MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ13373MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ13703MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW